Phaseline

Targets › INHBA

INHBA (Inhibin beta A chain): drug programs, companies and trials

3 programs from 3 companies in 16 trials: 7 Phase 2, 5 Phase 4, 3 Phase 3, 1 Phase 1; Cardiovascular, Oncology, Metabolic and endocrine; next expected readout Jul 2027.

Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition..; FUNCTION: Activin A is a homodimer of INHBA that plays a role in several…. (UniProt, P08476)

Open in Phaseline: the race on INHBA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Sotatercept (MK-7962)
Inhibin beta A chain inhibitor
INHBAPhase 4Pulmonary Arterial Hypertension; Hypertension, Pulmonary; Pulmonary Arterial Hypertension PAH; Eisenmenger Syndrome …Apr 2028
Regeneron PharmaceuticalsGaretosmab
Inhibin beta A chain inhibitor
INHBAPhase 3Fibrodysplasia Ossificans Progressiva; ObesityFeb 2029
Massachusetts General HospitalActivin ligand-trap biological therapy
Activin ligand trap (sequesters activin A and activin B)
INHBA, INHBBPhase 2Heart Failure With Preserved Ejection FractionJul 2027

Conditions

Pulmonary Arterial Hypertension (6) Hypertension, Pulmonary (1) Pulmonary Arterial Hypertension PAH (1) Eisenmenger Syndrome (1) Pulmonary Artery Hypertension (1) Pulmonary Arterial Hypertension (PAH) (1) Pulmonary Hypertension (1) Multiple Myeloma (1) Heart Failure With Preserved Ejection Fraction (1) Fibrodysplasia Ossificans Progressiva (1) Obesity (1)

Modalities

antibody (1), small molecule (1), mixed (1)

Companies

Merck & Co. (MSD) (1) Massachusetts General Hospital (1) Regeneron Pharmaceuticals (1)

Related targets

INHBB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.